Skip to content

Author

C. Gurnari

We have 7 of 417 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Emergency hematopoiesis in sepsis: A pathway to myeloid clonal expansion

Clonal hematopoiesis of indeterminate potential (CHIP) arises from somatic mutations in hematopoietic stem cells (HSCs) that confer a fitness advantage and is associated with increased risks of myeloid neoplasia, cardiovascular disease, and mortality. 1 – 5 Although aging is a major determinant of CHIP, the contributio...

Olisaemeka D. Ogbue, Tariq Kewan, Serhan Unlu et al. · 0 citations
Open access Nov 2026

Early hyperactivation and activation-associated mitochondrial abnormalities in GATA2 deficiency

Germline GATA2 deficiency is a hereditary disorder characterized by immunodeficiency, bone marrow failure, and a high risk of myelodysplastic neoplasms and acute myeloid leukemia (AML). Although abnormalities of innate immunity are well recognized, the phenotype and functional state of CD8 + T cells remain inco...

Marta Penco, M. Capelletti, Lorenzo Manfreda et al. · 0 citations
Open access Nov 2026

Salvage therapy for immune-mediated bone marrow failure.

Most acquired idiopathic bone marrow failure syndromes (BMFS) are thought to be cytotoxic T cell-mediated and are responsive to immunosuppressive therapies (IST) targeting T cells. However, in addition to frequent relapses, a proportion of cases remain refractory to first- and second-line agents due to a lack of clinic...

Serhan Unlu, Aashray Mandala, M. Orland et al. · 0 citations
Open access Sep 2026

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome in young adults: A retrospective study on behalf of the EBMT Chronic Malignancies Working Party.

Myelodysplastic syndromes (MDS) in young adults are uncommon and underrepresented in transplant cohorts. We evaluated 697 patients aged 18-40 years who underwent first allogeneic hematopoietic cell transplantation (allo-HCT) reported to the EBMT between 2016 and 2021. The primary endpoint was overall survival (OS); sec...

A. J. Jimenez Jimenez, D. Eikema, L. Koster et al. · 1 citation
Open access Sep 2026

Characterization of FLT3-ITD-mutated leukemic stem cells: functional and clinical insights

Despite treatment advances, relapsed/refractory FLT3 -ITD-mutated acute myeloid leukemia ( FLT3 -ITD mut AML) remains an unmet medical need. We previously identified a CD34/CD123/CD25/CD99+ leukemic progenitor cell (LPC) population that persists after induction treatment and drives disease recurrence in FLT3...

S. Travaglini, T. Ottone, S. Antonelli et al. · 0 citations
Open access Sep 2026

Healthcare Utilization Databases for Real-World Outcome Analysis of Ruxolitinib Treatment in Myelofibrosis

Introduction Myelofibrosis (MF) is a BRC::ABL1-negative myeloproliferative neoplasm characterised by a heterogeneous clinical phenotype encompassing abnormalities in blood counts, bone marrow fibrosis, splenomegaly, constitutional symptoms and vascular complications. MF may progress to accelerated phase (AP) and blast...

Barbara Mora, M. Franchi, L. Margotto et al. · 0 citations
Open access Sep 2026

iMTSS: an integrated framework for biology- and patient-driven prognosis in myelofibrosis undergoing transplantation.

Relapse and non-relapse mortality after transplantation for myelofibrosis are governed by distinct dimensions, and estimating both outcomes independently with genetic and clinical information, in addition to overall survival, establishes an individualized basis for transplant decision-making.

N. Gagelmann, R. Salit, T. Schroeder et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.